Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kane BiotechKNBIF -0.55% Days Sales Outstanding is 45.63 as of Mar. 2026, which is 19% below its 10-year median of 56.58. The stock has 6 warning signs investors should review. Among 836 Biotechnology companies, Kane Biotech ranks worse than 94.74% on this metric.
Kane Biotech's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.02 Mil. Kane Biotech's Revenue for the
three
months ended in Mar. 2026 was $0.03 Mil.
Hence, Kane Biotech's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 45.63.
The historical rank and industry rank for Kane Biotech's Days Sales Outstanding or its related term are showing as below:
KNBIF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.58 Med: 56.58 Max: 587.02
Current: 489.6
During the past 13 years, Kane Biotech's highest Days Sales Outstanding was 587.02. The lowest was 1.58. And the median was 56.58.
KNBIF's Days Sales Outstanding is ranked worse than 94.74% of 836
companies
in the Biotechnology industry
Industry Median: 68.52
vs KNBIF: 489.60
Kane Biotech's Days Sales Outstanding
increased
from Mar. 2025 (16.48) to Mar. 2026 (45.63).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Kane Biotech (OTCPK:KNBIF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Kane Biotech Days Sales Outstanding Related Terms
Kane Biotech Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Kane Biotech's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KNBIF vs VRTX, REGN, ALNY: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Kane Biotech's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kane Biotech Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kane Biotech's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Kane Biotech's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kane Biotech (KNBIF) has a Days Sales Outstanding of 45.63 as of Mar. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Kane Biotech and its competitors. This is 19% below median its historical median of 56.58. Over the past decade, Kane Biotech's Days Sales Outstanding has ranged from 1.58 to 587.02. According to the industry distribution chart, Kane Biotech ranks #792 out of 836 companies in the Biotechnology industry, placing it in the top 94.7%.
Is Kane Biotech's Days Sales Outstanding too high?
Kane Biotech's current Days Sales Outstanding of 45.63 is 19% below median its 10-year median of 56.58. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 587.02. The Biotechnology industry median Days Sales Outstanding is 68.52. Kane Biotech's value of 45.63 is 33.4% below this industry median. Based on the distribution chart, Kane Biotech ranks #792 out of 836 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Kane Biotech's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kane Biotech ranks #792 out of 836 companies for Days Sales Outstanding. This places Kane Biotech in the lower half of its industry. The industry median Days Sales Outstanding is 68.52. Kane Biotech's value of 45.63 is 33.4% below this benchmark. Historically, Kane Biotech's own Days Sales Outstanding has ranged from 1.58 to 587.02 over the past decade. While the company's 10-year median is 56.58 vs. the industry median of 68.52, Kane Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.52, based on 836 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kane Biotech's current Days Sales Outstanding of 45.63 is 33.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Kane Biotech and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kane Biotech's current Days Sales Outstanding is 45.63, which is 19% below median its own 10-year median of 56.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kane Biotech stock overvalued right now?
Kane Biotech (KNBIF) has a current Days Sales Outstanding of 45.63. The current Days Sales Outstanding is 45.63, which is 19% below median its 10-year median of 56.58 and 33.4% below the Biotechnology industry median of 68.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Kane Biotech (KNBIF), the current Days Sales Outstanding is 45.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The company's operating segments are animal health and human health. It derives maximum revenue from Animal health segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNBIF has been successfully added to your 
